The monoclonal antibody ustekinumab appears to be as effective as induction therapy in patients with ulcerative colitis who failed to respond to previous treatment, including other biologics, according to data from a large phase 3 study.
In addition to the primary end point of clinical remission at eight weeks, ustekinumab (Stelara, Janssen) produced greater responses on multiple measures including mucosal healing, said Bruce Sands, MD, the chief of the Division of Gastroenterology at the Icahn